2024-11-23 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis Report

**1. Performance Comparison & Alpha/Beta Analysis:**

Vertex Pharmaceuticals Inc. (VRTX) is a biotechnology company focused on the discovery, development, and commercialization of innovative medicines for serious diseases.

The cumulative return of VRTX is significantly higher than the S&P 500 (VOO) over the observed period.  The difference in cumulative returns is 39.07%, placing it in the 66.43rd percentile of its historical performance relative to the S&P 500.  This suggests VRTX has outperformed the market benchmark.

| Year       | CAGR    | MDD     | Alpha  | Beta  | Cap(B) |
|------------|---------|---------|--------|-------|--------|
| 2015-2017  | 21.8%   | 32.2%   | -16.6% | 1.6   | 38.6   |
| 2016-2018  | 34.8%   | 31.5%   | 2.5%   | 1.5   | 42.7   |
| 2017-2019  | 192.4%  | 19.1%   | 140.7% | 1.2   | 56.4   |
| 2018-2020  | 54.6%   | 30.4%   | 7.2%   | 0.9   | 60.9   |
| 2019-2021  | 33.8%   | 34.7%   | -66.2% | 0.8   | 56.5   |
| 2020-2022  | 31.6%   | 34.7%   | 8.0%   | 0.7   | 74.4   |
| 2021-2023  | 77.3%   | 21.3%   | 42.4%  | 0.6   | 104.8  |
| 2022-2024  | 102.7%  | 18.8%   | 72.6%  | 0.6   | 116.0  |

The alpha values fluctuate significantly, indicating periods of both outperformance and underperformance relative to the market.  The beta consistently sits above 1, showing higher volatility than the S&P 500.  The market capitalization has grown steadily over the years.

**2. Recent Price Movement:**

* **Closing Price:** 450.97
* **5-Day Moving Average:** 453.52
* **20-Day Moving Average:** 477.90
* **60-Day Moving Average:** 474.56

The price is below all three moving averages, suggesting a potential downward trend in the short term.

**3. Technical Indicators & Expected Return:**

* **RSI:** 42.3 (Approaching oversold territory, but not definitively so)
* **PPO:** -1.11 (Negative, indicating bearish momentum)
* **20-Day Relative Strength Change:** -13.77% (Significant recent weakening)
* **Expected Return (2+ years):** 17.79% (above S&P 500)

The technical indicators suggest a bearish short-term outlook. The relatively low RSI suggests the stock might be oversold, though not decisively. However, the negative PPO and significant drop in relative strength point towards a bearish trend.  The high expected return is a longer-term outlook.

**4. Recent Financial Performance:**

| Date       | EPS      | Revenue       |
|------------|----------|---------------|
| 2024-11-05 | 4.05     | $2.77 B       |
| 2024-08-02 | -13.92   | $2.65 B       |
| 2024-05-07 | 4.26     | $2.69 B       |
| 2023-11-07 | 4.01     | $2.48 B       |
| 2024-11-05 | 4.01     | $2.48 B       | *(Duplicate entry)*


The most recent EPS is positive (4.05), although significantly lower than the previous quarter. The large negative EPS in Q2 2024 needs investigation. Revenue remains relatively stable.  Further analysis is needed to determine the reasons for the fluctuating EPS and the duplicate entry.  Comparison to analyst expectations for the most recent quarter is crucial for a complete assessment.

**5.  Financial Statements (Revenue and Profitability & Capital and Profitability):**

**1) Revenue and Profitability:**

| Quarter     | Revenue    | Profit Margin |
|-------------|------------|----------------|
| 2024-09-30  | $2.77B     | 85.84%         |
| 2024-06-30  | $2.65B     | 85.94%         |
| 2024-03-31  | $2.69B     | 87.27%         |
| 2023-12-31  | $2.52B     | 85.38%         |
| 2023-09-30  | $2.48B     | 87.17%         |

Profit margins remain consistently high, indicating strong profitability.  Revenue growth is relatively stable.

**2) Capital and Profitability:**

| Quarter     | Equity     | ROE          |
|-------------|------------|---------------|
| 2024-09-30  | $15.63B    | 6.69%         |
| 2024-06-30  | $14.77B    | -24.32%       |
| 2024-03-31  | $18.55B    | 5.93%         |
| 2023-12-31  | $17.58B    | 5.51%         |
| 2023-09-30  | $16.51B    | 6.27%         |

The significant negative ROE in Q2 2024 requires thorough investigation.  This warrants further analysis to understand the underlying causes.

**6. News and Recent Issues:**

*(This section requires access to real-time news sources such as Seeking Alpha, Yahoo Finance, and company press releases to provide information on recent news and analyst opinions within the last two days.  Please provide those sources.)*  The analysis would include any recent earnings announcements, changes in analyst ratings, significant market events impacting the stock, and other relevant news.  FINBOLD and similar sources can also help establish current market outlook and analyst consensus.

**7.  Overall Analysis:**

VRTX has shown strong long-term growth significantly outperforming the S&P 500. However, recent financial performance, especially the negative EPS and ROE in Q2 2024, requires detailed investigation.  The short-term outlook appears bearish based on technical indicators, though the RSI suggests a potential oversold condition. The significant negative change in relative strength needs further exploration. The long-term outlook remains positive based on the predicted higher return than the S&P 500.  News and analyst opinions are crucial for a comprehensive assessment of current market sentiment and future prospects.  A thorough analysis of the reasons for the Q2 2024 results is essential before making any investment decisions.


**8. Disclaimer:** This report is for informational purposes only and does not constitute financial advice.  Investment decisions should be made based on your own research and risk tolerance.  Consult with a financial advisor before making any investment decisions.
